US4450150A
(en)
|
1973-05-17 |
1984-05-22 |
Arthur D. Little, Inc. |
Biodegradable, implantable drug delivery depots, and method for preparing and using the same
|
EP0272253A4
(en)
|
1986-03-07 |
1990-02-05 |
Massachusetts Inst Technology |
METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
JPH02500329A
(ja)
|
1987-05-21 |
1990-02-08 |
クリエイテイブ・バイオマリキユールズ・インコーポレーテツド |
ターゲット化多機能蛋白質
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
CA2050918A1
(en)
|
1990-01-12 |
1991-07-13 |
Raju Kucherlapati |
Generation of xenogeneic antibodies
|
US6673986B1
(en)
|
1990-01-12 |
2004-01-06 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
ES2108048T3
(es)
|
1990-08-29 |
1997-12-16 |
Genpharm Int |
Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
|
US6770274B1
(en)
|
1990-09-14 |
2004-08-03 |
The General Hospital Corporation |
Viral mutant HSV mediated destruction of neoplastic cells
|
US5780279A
(en)
|
1990-12-03 |
1998-07-14 |
Genentech, Inc. |
Method of selection of proteolytic cleavage sites by directed evolution and phagemid display
|
DE69129154T2
(de)
|
1990-12-03 |
1998-08-20 |
Genentech Inc |
Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
|
JP3266311B2
(ja)
|
1991-05-02 |
2002-03-18 |
生化学工業株式会社 |
新規ポリペプチドおよびこれを用いる抗hiv剤
|
DE69230142T2
(de)
|
1991-05-15 |
2000-03-09 |
Cambridge Antibody Tech |
Verfahren zur herstellung von spezifischen bindungspaargliedern
|
US5858657A
(en)
|
1992-05-15 |
1999-01-12 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
US6225447B1
(en)
|
1991-05-15 |
2001-05-01 |
Cambridge Antibody Technology Ltd. |
Methods for producing members of specific binding pairs
|
GB9206422D0
(en)
|
1992-03-24 |
1992-05-06 |
Bolt Sarah L |
Antibody preparation
|
US7381803B1
(en)
|
1992-03-27 |
2008-06-03 |
Pdl Biopharma, Inc. |
Humanized antibodies against CD3
|
US5855885A
(en)
|
1993-01-22 |
1999-01-05 |
Smith; Rodger |
Isolation and production of catalytic antibodies using phage technology
|
US6699468B1
(en)
|
1994-06-23 |
2004-03-02 |
Georgetown University |
Replication-competent herpes simplex virus mediates destruction of neoplastic cells
|
US5728379A
(en)
|
1994-06-23 |
1998-03-17 |
Georgetown University |
Tumor- or cell-specific herpes simplex virus replication
|
US5585096A
(en)
|
1994-06-23 |
1996-12-17 |
Georgetown University |
Replication-competent herpes simplex virus mediates destruction of neoplastic cells
|
US5702892A
(en)
|
1995-05-09 |
1997-12-30 |
The United States Of America As Represented By The Department Of Health And Human Services |
Phage-display of immunoglobulin heavy chain libraries
|
US6265150B1
(en)
|
1995-06-07 |
2001-07-24 |
Becton Dickinson & Company |
Phage antibodies
|
US5714352A
(en)
|
1996-03-20 |
1998-02-03 |
Xenotech Incorporated |
Directed switch-mediated DNA recombination
|
US5824318A
(en)
|
1996-07-24 |
1998-10-20 |
American Cyanamid Company |
Avirulent herpetic viruses useful as tumoricidal agents and vaccines
|
ATE549918T1
(de)
|
1996-12-03 |
2012-04-15 |
Amgen Fremont Inc |
Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
|
US6057098A
(en)
|
1997-04-04 |
2000-05-02 |
Biosite Diagnostics, Inc. |
Polyvalent display libraries
|
US6379674B1
(en)
|
1997-08-12 |
2002-04-30 |
Georgetown University |
Use of herpes vectors for tumor therapy
|
CN1296417A
(zh)
|
1998-02-10 |
2001-05-23 |
卫福有限公司 |
控释制剂
|
HU229039B1
(en)
|
1998-04-21 |
2013-07-29 |
Amgen Res Munich Gmbh |
Cd19xcd3 specific polypeptides and uses thereof
|
GB9815909D0
(en)
|
1998-07-21 |
1998-09-16 |
Btg Int Ltd |
Antibody preparation
|
GB2344287A
(en)
|
1998-12-03 |
2000-06-07 |
Ferring Bv |
Controlled release pharmaceutical formulation
|
WO2000040734A1
(en)
|
1998-12-31 |
2000-07-13 |
Arch Development Corporation |
Recombinant herpes simplex virus useful for treating neoplastic disease
|
US6307024B1
(en)
|
1999-03-09 |
2001-10-23 |
Zymogenetics, Inc. |
Cytokine zalpha11 Ligand
|
AU2905199A
(en)
|
1999-03-15 |
2000-10-04 |
Trustees Of The University Of Pennsylvania, The |
Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
|
US6764675B1
(en)
|
1999-06-08 |
2004-07-20 |
The Uab Research Foundation |
Herpes simplex virus expressing foreign genes and method for treating cancers therewith
|
US6833268B1
(en)
|
1999-06-10 |
2004-12-21 |
Abgenix, Inc. |
Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
|
ATE282708T1
(de)
|
2000-01-21 |
2004-12-15 |
Biovex Ltd |
Herpes-virusstämme für die gentherapie
|
JP2004511425A
(ja)
|
2000-02-08 |
2004-04-15 |
ザ ペン ステート リサーチ ファウンデーション |
免疫療法に使用されるインターロイキン13受容体サブユニットアルファー2
|
AU2002306919B2
(en)
|
2001-03-27 |
2007-11-22 |
Tomoki Todo |
Viral vectors and their use in therapeutic methods
|
AR036993A1
(es)
*
|
2001-04-02 |
2004-10-20 |
Wyeth Corp |
Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
|
DK1451322T3
(da)
|
2001-11-05 |
2010-02-01 |
Zymogenetics Inc |
Il-21-antagonister
|
JP2005512044A
(ja)
|
2001-12-03 |
2005-04-28 |
アブジェニックス・インコーポレーテッド |
結合特性に基づく抗体分類
|
US7494804B2
(en)
|
2002-01-18 |
2009-02-24 |
Zymogenetics, Inc. |
Polynucleotide encoding cytokine receptor zcytor17 multimer
|
US7736652B2
(en)
|
2002-03-21 |
2010-06-15 |
The Regents Of The University Of California |
Antibody fusion proteins: effective adjuvants of protein vaccination
|
EP2377547A1
(en)
|
2002-06-07 |
2011-10-19 |
ZymoGenetics, Inc. |
Use of IL-21 as an antimicrobial agent
|
DE60331455D1
(de)
|
2002-10-04 |
2010-04-08 |
Microchips Inc |
Medizinische vorrichtung zur gesteuerten arzneimittelverabreichung sowie herzüberwachung und/oder herzstimulation
|
CN1513993A
(zh)
|
2002-12-31 |
2004-07-21 |
北京博泰迪生物工程科技开发有限公司 |
中国人基因组cDNA文库白细胞介素21的编码基因序列及其蛋白质的氨基酸序列
|
AU2004242846A1
(en)
|
2003-05-31 |
2004-12-09 |
Micromet Ag |
Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
|
AU2004275871A1
(en)
|
2003-09-25 |
2005-04-07 |
Zymogenetics, Inc. |
Methods of treating autoimmune diseases using IL-21
|
RU2401843C2
(ru)
|
2003-10-16 |
2010-10-20 |
Микромет Аг |
Полиспецифические деиммунизирующие cd3-связующие
|
KR101266716B1
(ko)
|
2004-06-03 |
2013-05-31 |
노비뮨 에스 에이 |
항-cd3 항체 및 그의 사용 방법
|
US7731952B2
(en)
|
2004-06-24 |
2010-06-08 |
New York University |
Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
|
CA2599925A1
(en)
|
2005-03-14 |
2006-09-21 |
Merck & Co., Inc. |
Cgrp receptor antagonists
|
MX2007012887A
(es)
|
2005-04-18 |
2007-12-10 |
Novo Nordisk As |
Variantes il-21.
|
CN105315373B
(zh)
|
2005-05-09 |
2018-11-09 |
小野药品工业株式会社 |
程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
|
JP2009517406A
(ja)
|
2005-11-28 |
2009-04-30 |
ザイモジェネティクス, インコーポレイテッド |
Il−21受容体アンタゴニスト
|
EP1963369B1
(en)
|
2005-11-28 |
2013-05-15 |
Zymogenetics, Inc. |
Il-21 antagonists
|
TW200745163A
(en)
|
2006-02-17 |
2007-12-16 |
Syntonix Pharmaceuticals Inc |
Peptides that block the binding of IgG to FcRn
|
EA200802289A1
(ru)
|
2006-05-08 |
2009-04-28 |
Филоджен Спа |
Направляемые к мишени антителами цитокины для терапии
|
WO2008049920A2
(en)
|
2006-10-26 |
2008-05-02 |
Novo Nordisk A/S |
Il-21 variants
|
EP2109620B1
(en)
|
2006-12-21 |
2012-08-22 |
Novo Nordisk A/S |
Interleukin-21 variants with altered binding to the il-21 receptor
|
CN101230334B
(zh)
|
2007-01-22 |
2011-06-01 |
北京奥源和力生物技术有限公司 |
单纯疱疹病毒和重组病毒及宿主细胞及其药物组合物
|
CN101230335B
(zh)
|
2007-01-22 |
2010-08-11 |
北京奥源和力生物技术有限公司 |
单纯疱疹病毒和重组病毒及宿主细胞及其药物组合物
|
CA2683370C
(en)
|
2007-04-03 |
2022-12-13 |
Micromet Ag |
Cross-species-specific binding domain
|
WO2008119567A2
(en)
|
2007-04-03 |
2008-10-09 |
Micromet Ag |
Cross-species-specific cd3-epsilon binding domain
|
KR101034888B1
(ko)
|
2007-04-19 |
2011-05-17 |
동아제약주식회사 |
지속제어 방출 양상을 갖는 당조절 펩타이드 함유 생분해성고분자 미립구 및 그 제조방법
|
CA2707026C
(en)
|
2007-12-07 |
2017-04-11 |
Zymogenetics, Inc. |
Anti-human il-21 monoclonal antibodies
|
WO2009114335A2
(en)
*
|
2008-03-12 |
2009-09-17 |
Merck & Co., Inc. |
Pd-1 binding proteins
|
US8217140B2
(en)
|
2008-04-17 |
2012-07-10 |
Ablynx N.V. |
Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
|
WO2010027828A2
(en)
*
|
2008-08-25 |
2010-03-11 |
Amplimmune, Inc. |
Pd-1 antagonists and methods of use thereof
|
ES2588155T3
(es)
|
2008-10-01 |
2016-10-31 |
Amgen Research (Munich) Gmbh |
Anticuerpo biespecífico de cadena sencilla PSMAxCD3 específico entre especies
|
EP2406282A1
(en)
*
|
2009-03-11 |
2012-01-18 |
Novo Nordisk A/S |
Interleukin-21 variants having antagonistic binding to the il-21 receptor
|
WO2010112193A1
(en)
|
2009-04-02 |
2010-10-07 |
Roche Glycart Ag |
Multispecific antibodies comprising full length antibodies and single chain fab fragments
|
PT2975051T
(pt)
|
2009-06-26 |
2021-05-04 |
Regeneron Pharma |
Anticorpos biespecíficos rapidamente isolados com formato de imunoglobulina nativa
|
KR20120053042A
(ko)
|
2009-08-17 |
2012-05-24 |
로슈 글리카트 아게 |
표적화된 면역접합체
|
MX2012004793A
(es)
|
2009-10-30 |
2012-07-20 |
Novozymes Biopharma Dk As |
Variantes de albumina.
|
PL2542590T5
(pl)
|
2010-03-05 |
2020-08-10 |
The Johns Hopkins University |
Kompozycje i sposoby dla ukierunkowanych immunomodulatorowych przeciwciał i białek fuzyjnych
|
CN103347893A
(zh)
|
2010-11-01 |
2013-10-09 |
诺维信生物制药丹麦公司 |
白蛋白变体
|
EP2672999A2
(en)
|
2011-02-10 |
2013-12-18 |
Roche Glycart AG |
Improved immunotherapy
|
CA2829628A1
(en)
|
2011-03-11 |
2012-09-20 |
Amgen Inc. |
Method of correlated mutational analysis to improve therapeutic antibodies
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
US8822417B2
(en)
|
2011-05-05 |
2014-09-02 |
Novozymes Biopharma DIC A/S |
Albumin variants
|
EP2723380B1
(en)
|
2011-06-24 |
2019-08-21 |
Stephen D. Gillies |
Light chain immunoglobulin fusion proteins and methods of use thereof
|
WO2013006795A2
(en)
|
2011-07-07 |
2013-01-10 |
Humanitas International Foundation |
Antiviral compositions and methods of their use
|
DK2753355T3
(en)
|
2011-09-08 |
2019-01-28 |
Univ New York |
ONCOLYTIC HERP SIMPLEX VIRUSES AND THERAPEUTIC APPLICATIONS THEREOF
|
BR112014009925B1
(pt)
|
2011-10-28 |
2022-09-20 |
Teva Pharmaceuticals Australia Pty Ltd |
Construtores de polipeptídeos e seus usos
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對bcma之e3以及cd3的結合分子
|
EP2780364A2
(en)
|
2011-11-18 |
2014-09-24 |
Eleven Biotherapeutics, Inc. |
Proteins with improved half-life and other properties
|
WO2013096732A2
(en)
|
2011-12-23 |
2013-06-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of treating or preventing viral diseases by blocking interleukin-21
|
US9447160B2
(en)
|
2012-01-19 |
2016-09-20 |
University Of Miami |
Compositions, methods and kits for treatment of cancer and autoimmune diseases
|
BR112014018679A2
(pt)
|
2012-03-16 |
2017-07-04 |
Novozymes Biopharma Dk As |
variantes de albumina
|
NZ714549A
(en)
|
2012-04-30 |
2016-10-28 |
Biocon Ltd |
Targeted/immunomodulatory fusion proteins and methods for making same
|
WO2013169734A1
(en)
|
2012-05-07 |
2013-11-14 |
Amgen Inc. |
Anti-erythropoietin antibodies
|
WO2013169693A1
(en)
*
|
2012-05-09 |
2013-11-14 |
Bristol-Myers Squibb Company |
Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
|
CA2872195A1
(en)
|
2012-08-07 |
2014-02-13 |
Roche Glycart Ag |
Composition comprising two antibodies engineered to have reduced and increased effector function
|
EP2917233A1
(en)
|
2012-11-08 |
2015-09-16 |
Novozymes Biopharma DK A/S |
Albumin variants
|
CN105518143B
(zh)
|
2013-03-15 |
2020-02-21 |
北京凯得尔森生物技术有限公司 |
融合蛋白分子和它的使用方法
|
PT2992017T
(pt)
|
2013-05-02 |
2021-01-29 |
Anaptysbio Inc |
Anticorpos dirigidos contra a morte programada 1 (pd-1)
|
WO2015000585A1
(en)
|
2013-07-02 |
2015-01-08 |
Walter Sebald |
Muteins of cytokines of the gamma-chain receptor family conjugated to a non-protein group
|
EP3019531A4
(en)
|
2013-07-11 |
2017-03-15 |
The California Institute for Biomedical Research |
Immunoglobulin fusion proteins and compositions thereof
|
RS59480B1
(sr)
|
2013-12-12 |
2019-12-31 |
Shanghai hengrui pharmaceutical co ltd |
Pd-1 antitelo, njegov fragment koji se vezuje na antigen, i njegova medicinska primena
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對pd-1的人類抗體
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JP2017506075A
(ja)
|
2014-02-06 |
2017-03-02 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
インターロイキン−10イムノコンジュゲート
|
CA2940018C
(en)
|
2014-02-19 |
2018-12-04 |
Merck Patent Gmbh |
Cancer-targeted il-12 immunotherapy
|
CA3208721A1
(en)
|
2014-04-08 |
2015-10-15 |
Boston Pharmaceuticals Inc. |
Binding molecules specific for il-21 and uses thereof
|
CN104403004B
(zh)
|
2014-11-24 |
2017-10-13 |
苏州丁孚靶点生物技术有限公司 |
抗体‑干扰素异二聚体的制备和用途
|
EP3233192B1
(en)
|
2014-12-15 |
2021-04-14 |
Washington University |
Compositions and methods for targeted cytokine delivery
|
US10662240B2
(en)
|
2014-12-19 |
2020-05-26 |
Mabtech Ab |
Composition, kit and method for inhibition of IL-21 mediated activation of human cells
|
WO2016094962A1
(en)
|
2014-12-19 |
2016-06-23 |
Monash University |
Il-21 antibodies
|
KR20160113452A
(ko)
|
2015-03-20 |
2016-09-29 |
(주)엘지하우시스 |
진공 단열재용 심재 및 진공단열재
|
EA201890296A1
(ru)
|
2015-07-30 |
2018-08-31 |
Макродженикс, Инк. |
Pd-1-связывающие молекулы и способы их применения
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究(慕尼黑)公司 |
Flt3及cd3抗體構築體
|
TW202346349A
(zh)
|
2015-07-31 |
2023-12-01 |
德商安美基研究(慕尼黑)公司 |
Dll3及cd3抗體構築體
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究(慕尼黑)公司 |
Egfrviii及cd3抗體構築體
|
US20180221503A1
(en)
|
2015-07-31 |
2018-08-09 |
Tarveda Therapeutics, Inc. |
Compositions and methods for immuno-oncology therapies
|
MX2018001644A
(es)
|
2015-08-11 |
2018-11-09 |
Wuxi Biologics Cayman Inc |
Anticuerpos anti-pd-1 novedosos.
|
CN114605548A
(zh)
|
2015-09-01 |
2022-06-10 |
艾吉纳斯公司 |
抗-pd-1抗体及其使用方法
|
IL257858B
(en)
|
2015-10-02 |
2022-09-01 |
Hoffmann La Roche |
Antibodies against pd1 and methods of their use
|
MA43186B1
(fr)
|
2015-11-03 |
2022-03-31 |
Janssen Biotech Inc |
Anticorps se liant spécifiquement à pd-1 et leurs utilisations
|
WO2017077382A1
(en)
|
2015-11-06 |
2017-05-11 |
Orionis Biosciences Nv |
Bi-functional chimeric proteins and uses thereof
|
HRP20231156T1
(hr)
*
|
2015-12-22 |
2024-01-05 |
Regeneron Pharmaceuticals, Inc. |
Kombinacija anti-pd-1 antitijela i bispecifičnih anti-cd20/anti-cd3 antitijela za liječenje raka
|
JP6959258B2
(ja)
|
2016-01-08 |
2021-11-02 |
レプリミュン リミテッド |
改変された腫瘍溶解性ウイルス
|
EP3402508A4
(en)
|
2016-01-11 |
2019-09-25 |
Flagship Pioneering Innovations V, Inc. |
METHOD AND COMPOSITIONS FOR MODULATING THE THYMUS FUNCTION
|
EP3411402B1
(en)
|
2016-02-03 |
2021-12-22 |
Amgen Research (Munich) GmbH |
Bcma and cd3 bispecific t cell engaging antibody constructs
|
DK3411404T3
(da)
|
2016-02-03 |
2023-01-30 |
Amgen Res Munich Gmbh |
Psma- og cd3-bispecifikke t-celleinddragende antistofkonstruktioner
|
EA039859B1
(ru)
|
2016-02-03 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
EP3411407B1
(en)
|
2016-02-05 |
2024-04-03 |
Orionis Biosciences BV |
Bispecific signaling agents and uses thereof
|
CN109071679B
(zh)
|
2016-02-05 |
2023-07-28 |
华盛顿大学 |
用于靶向的细胞因子递送的组合物和方法
|
EP3430055B1
(en)
|
2016-03-17 |
2020-10-28 |
Oslo Universitetssykehus HF |
Fusion proteins targeting tumour associated macrophages for treating cancer
|
CN109153728A
(zh)
|
2016-03-21 |
2019-01-04 |
埃尔斯塔治疗公司 |
多特异性和多功能分子及其用途
|
MA44507A
(fr)
|
2016-04-01 |
2019-02-06 |
Amgen Inc |
Récepteurs chimères de flt3 et leurs procédés d'utilisation
|
WO2017181420A1
(en)
|
2016-04-22 |
2017-10-26 |
Immuno Vir Co., Limited |
CONSTRUCTION OF ONCOLYTIC HERPES SIMPLEX VIRUSES (oHSV) OBLIGATE VECTOR AND CONSTRUCTS FOR CANCER THERAPY
|
WO2018006005A1
(en)
|
2016-06-30 |
2018-01-04 |
Oncorus, Inc. |
Pseudotyped oncolytic viral delivery of therapeutic polypeptides
|
RU2656181C1
(ru)
|
2016-07-13 |
2018-05-31 |
Закрытое Акционерное Общество "Биокад" |
Анти-pd-1-антитела, способ их получения и способ применения
|
EP3490583B1
(en)
|
2016-08-01 |
2023-11-29 |
Virogin Biotech Canada Ltd |
Oncolytic herpes simplex virus vectors expressing immune system-stimulatory molecules
|
KR101928981B1
(ko)
|
2016-09-02 |
2018-12-13 |
고려대학교 산학협력단 |
항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 IL-21 (heterodimeric Fc-fused IL-21) 및 이를 포함하는 약제학적 조성물
|
CN109952316A
(zh)
|
2016-09-14 |
2019-06-28 |
北京韩美药品有限公司 |
一种能够特异性地结合pd-1的抗体及其功能片段
|
KR102273634B1
(ko)
|
2016-09-21 |
2021-07-07 |
씨스톤 파마슈티컬즈 |
예정 사멸 1(pd-1)에 대한 신규한 단일클론성 항체
|
EP3515472A4
(en)
|
2016-09-23 |
2020-04-29 |
OncoSec Medical Incorporated |
MODULATION OF REACTIONS ON CHECKPOINT INHIBITOR THERAPY
|
MA46708B1
(fr)
|
2016-11-02 |
2021-10-29 |
Jounce Therapeutics Inc |
Anticorps anti-pd1 et leurs utilisations
|
GB201700350D0
(en)
|
2017-01-09 |
2017-02-22 |
Replimune Ltd |
Altered virus
|
CN107082812B
(zh)
|
2017-03-29 |
2018-11-13 |
上海科医联创生物科技有限公司 |
一种恢复衰竭性免疫细胞功能的融合蛋白及其应用
|
CN117003887A
(zh)
|
2017-04-03 |
2023-11-07 |
豪夫迈·罗氏有限公司 |
抗pd-1抗体与突变体il-2或与il-15的免疫缀合物
|
CN111094330A
(zh)
|
2017-07-03 |
2020-05-01 |
转矩医疗股份有限公司 |
编码免疫刺激融合分子的多核苷酸及其用途
|
US20210260163A1
(en)
|
2018-03-09 |
2021-08-26 |
AskGene Pharma, Inc. |
Novel cytokine prodrugs
|
AU2019243580A1
(en)
|
2018-03-28 |
2020-11-12 |
Orionis Biosciences BV |
Bi-functional proteins and construction thereof
|
US20210163621A1
(en)
|
2018-04-10 |
2021-06-03 |
Amgen Inc. |
Chimeric receptors to dll3 and methods of use thereof
|
EP3807321A4
(en)
|
2018-06-18 |
2022-03-02 |
Anwita Biosciences, Inc. |
ANTI-MESOTHELIN CONSTRUCTS AND USES THEREOF
|
CN113164558A
(zh)
|
2018-09-28 |
2021-07-23 |
皮埃尔法布雷医药公司 |
用于治疗癌症的新型免疫细胞因子
|
US20220025050A1
(en)
|
2018-12-21 |
2022-01-27 |
Ose Immunotherapeutics |
Bifunctional molecule directed against human pd-1
|